Capsule Summary Slidesets

Share

Program Content

Activities

  • Ziftomenib in AML
    Phase I/II KOMET-001: First-in-Human Study of Ziftomenib, a Novel KMT2A-Menin Inhibitor, in Relapsed/Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2022

    Expires: December 11, 2023

    View Activity
  • ASC4MORE: Addition of Asciminib to Imatinib
    ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2022

    Expires: December 12, 2023

    View Activity
  • ECOG-ACRIN E1910
    ECOG-ACRIN E1910: Phase III Study of Consolidation Chemotherapy ± Blinatumomab in MRD-Negative BCR::ABL1-Negative B-ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2022

    Expires: December 14, 2023

    View Activity
  • AUGMENT-101: Revumenib
    AUGMENT-101: Phase I Study of Revumenib in Patients With KMT2A-Rearranged or NPM1-Mutant AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2022

    Expires: December 14, 2023

    View Activity
  • Gilteritinib/Aza/Ven/ in <em>FLT3</em>-Mut AML
    Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2022

    Expires: December 14, 2023

    View Activity
  • Low-Dose Dasatinib in CML
    Low-Dose Dasatinib for Newly Diagnosed CML: Long-term Follow-up Outcomes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • GRAALL-2014/B QUEST
    GRAALL-2014/B Quest Cohort Analysis: Blinatumomab During Consolidation in Adults With High-Risk Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • VIALE-A Extended Follow-up
    VIALE-A: Extended Follow-up of Azacitidine ± Venetoclax in Patients With Treatment-Naive AML Ineligible for Standard Induction Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • V-FAST FLT3 Subgroup
    V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2022

    Expires: December 16, 2023

    View Activity
  • PhI/II AZA/VEN/MAG
    Phase I/II Trial of Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

    View Activity
  • GMALL-INITIAL1
    GMALL-INITIAL1: Inotuzumab Ozogamicin Induction Therapy Followed by Standard Chemotherapy in Older Patients With B-Lymphoblastic Leukemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2022

    Expires: December 18, 2023

    View Activity

Provided by

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen